Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-response study of BMS-562247 for venous thromboembolism prevention after elective total knee replacement
2004-001128-19Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of apixaban in venous thromboembolism (VTE), deep vein thrombosis (DVT) and pulmonary embolism (PE) (8 arms), sponsored by Bristol Myers Squibb. Started Sep 2004; status: completed.
02
Drugs
apixaban
03
Conditions
venous thromboembolism (VTE)deep vein thrombosis (DVT)pulmonary embolism (PE)
Beyond the preview
Go deeper on 2004-001128-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001128-19.